{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-091463","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.465470+00:00","generated_at":"2026-06-04T00:25:54.418309+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)","bullets":["C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.","HbA1c reduced by 0.26% on average; 6 of 8 improved; time in target glucose range improved by +7.1%.","Visual acuity improved in 5 of 8 participants; one participant changed from legally blind to sighted.","All 8 participants showed disease stability or improvement per CGIC and PGIC; no serious AEs related to AMX0035."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-091463","json":"https://secwatch.observer/filing/0001193125-24-091463.json","markdown":"https://secwatch.observer/filing/0001193125-24-091463.md","text":"https://secwatch.observer/filing/0001193125-24-091463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/0001193125-24-091463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/d818999d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:25:54.418309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}